Oncoepigenomics: making histone lysine methylation count.

[1]  P. Northcott,et al.  Targeting the enhancer of zeste homologue 2 in medulloblastoma , 2012, International journal of cancer.

[2]  P. K. Bajpe,et al.  Targeting the epigenome for treatment of cancer , 2012, Oncogene.

[3]  Gillian H. Little,et al.  Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription , 2012, Journal of cellular biochemistry.

[4]  A. Iwama,et al.  3‐Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor‐initiating hepatocellular carcinoma cells , 2012, International journal of cancer.

[5]  Y. Jeng,et al.  H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. , 2012, Cancer research.

[6]  T. Lv,et al.  Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer , 2012, PloS one.

[7]  Jun Yao,et al.  G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. , 2012, The Journal of clinical investigation.

[8]  B. Garcia,et al.  Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation , 2012, Epigenetics.

[9]  L. Altucci,et al.  Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1 , 2012, Leukemia.

[10]  S. Armstrong,et al.  Polycomb repressive complex 2 is required for MLL-AF9 leukemia , 2012, Proceedings of the National Academy of Sciences.

[11]  K. Shin‐ya,et al.  Inhibition of histone H3K9 methyltransferases by gliotoxin and related epipolythiodioxopiperazines , 2012, The Journal of Antibiotics.

[12]  J. Weitzman,et al.  SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. , 2012, Cancer research.

[13]  古家 由理,et al.  岐阜及び愛知県内で分離された肺炎球菌の各種抗菌薬に対する感受性サーベイランス(2008年~2009年) , 2012 .

[14]  Jeong-Ho Kim,et al.  The Role of EZH2 in the Regulation of the Activity of Matrix Metalloproteinases in Prostate Cancer Cells , 2012, PloS one.

[15]  S. González,et al.  Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease , 2012, Nature Communications.

[16]  Jong-Wan Park,et al.  Deficiency of H3K79 Histone Methyltransferase Dot1-like Protein (DOT1L) Inhibits Cell Proliferation* , 2011, The Journal of Biological Chemistry.

[17]  J. Armitage,et al.  25 Years Later: Endangered Species or Successful Evolution? , 2011 .

[18]  N. Harris,et al.  EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas , 2011, PloS one.

[19]  W. Reardon,et al.  How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum , 2011, European Journal of Human Genetics.

[20]  M. Frye,et al.  The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin , 2011, The EMBO journal.

[21]  S. Armstrong,et al.  A role for DOT1L in MLL-rearranged leukemias. , 2011, Epigenomics.

[22]  Lothar Hennighausen,et al.  EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer , 2011, International journal of biological sciences.

[23]  B. Garcia,et al.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. , 2011, Molecular cell.

[24]  E. Celis,et al.  Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer , 2011, Journal of Translational Medicine.

[25]  F. Liu,et al.  Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy , 2011, Clinical Cancer Research.

[26]  Yongcheng Song,et al.  Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. , 2011, Journal of the American Chemical Society.

[27]  N. Keen,et al.  Structural basis of substrate methylation and inhibition of SMYD2. , 2011, Structure.

[28]  Jidong Zhu,et al.  Structure of Human SMYD2 Protein Reveals the Basis of p53 Tumor Suppressor Methylation* , 2011, The Journal of Biological Chemistry.

[29]  F. Rossi,et al.  p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. , 2011, Molecular cell.

[30]  S. Campaner,et al.  The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. , 2011, Molecular cell.

[31]  B. Ponder,et al.  Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. , 2011, Neoplasia.

[32]  Peter A. DiMaggio,et al.  A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. , 2011, Nature chemical biology.

[33]  M. Fälth,et al.  EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells , 2011, PloS one.

[34]  S. Armstrong,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[35]  O. Gozani,et al.  Regulation of p53 function by lysine methylation. , 2011, Epigenomics.

[36]  S. Schreiber,et al.  A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. , 2011, Journal of the American Chemical Society.

[37]  Takayoshi Suzuki,et al.  Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. , 2011, Bioorganic & medicinal chemistry.

[38]  G. Packham,et al.  Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. , 2011, Bioorganic & medicinal chemistry.

[39]  T. Heightman,et al.  Inhibition of Histone Demethylases by 4‐Carboxy‐2,2′‐Bipyridyl Compounds , 2011, ChemMedChem.

[40]  G. Packham,et al.  S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition , 2011, Breast Cancer Research and Treatment.

[41]  David A. Orlando,et al.  The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma , 2011, Nature.

[42]  J. Issa,et al.  Epigenetics in cancer: what's the future? , 2011, Oncology.

[43]  T. Hornyak,et al.  EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression , 2011, Molecular Cancer Research.

[44]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[45]  B. Ponder,et al.  Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers , 2011, International journal of cancer.

[46]  T. Heightman,et al.  Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates. , 2011, Organic & biomolecular chemistry.

[47]  D. Bayarsaihan.  Epigenetic Mechanisms in Inflammation , 2011, Journal of dental research.

[48]  H. Kagechika,et al.  Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9. , 2010, Bioorganic & medicinal chemistry.

[49]  R. David.  Cell cycle: Disposing of SETD8 , 2010, Nature Reviews Molecular Cell Biology.

[50]  A. Jadhav,et al.  Quantitative High-Throughput Screening Identifies 8-Hydroxyquinolines as Cell-Active Histone Demethylase Inhibitors , 2010, PloS one.

[51]  Qiang Yu,et al.  The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. , 2010, Blood.

[52]  Kristian Helin,et al.  Histone demethylases in development and disease. , 2010, Trends in cell biology.

[53]  J. Yates,et al.  Methylation of the Retinoblastoma Tumor Suppressor by SMYD2* , 2010, The Journal of Biological Chemistry.

[54]  Anton Simeonov,et al.  Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. , 2010, Journal of medicinal chemistry.

[55]  N. McCarthy.  Leukaemia: MLL makes friends and influences , 2010, Nature Reviews Cancer.

[56]  Shiv k. Sharma,et al.  (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.

[57]  Makoto Hasegawa,et al.  Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. , 2010, Journal of medicinal chemistry.

[58]  T. Umehara,et al.  Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 . , 2010, Biochemistry.

[59]  Aiming Sun,et al.  Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. , 2010, Journal of molecular biology.

[60]  R. Natarajan,et al.  The role of epigenetics in the pathology of diabetic complications. , 2010, American journal of physiology. Renal physiology.

[61]  C. Allis,et al.  Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. , 2010, Molecular cell.

[62]  A. Mai,et al.  Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. , 2010, Journal of the American Chemical Society.

[63]  K. Helin,et al.  Histone methyltransferases in cancer. , 2010, Seminars in cell & developmental biology.

[64]  P. Cole,et al.  Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. , 2010, Journal of the American Chemical Society.

[65]  M. Sodeoka,et al.  Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. , 2010, Journal of the American Chemical Society.

[66]  R. Schüle,et al.  Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.

[67]  Christopher J. Schofield,et al.  Selective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic Approaches† , 2010, Journal of medicinal chemistry.

[68]  Paul Greengard,et al.  Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity , 2010, Science.

[69]  Anton Simeonov,et al.  Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. , 2009, Journal of medicinal chemistry.

[70]  D. Reinberg,et al.  TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88 Recruitment to Control Ras-dependent Amplification of NF-κB* , 2009, The Journal of Biological Chemistry.

[71]  S. Baylin,et al.  Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes , 2009, Clinical Cancer Research.

[72]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[73]  S. Sugano,et al.  Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. , 2009, Biochemical and biophysical research communications.

[74]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[75]  M. J. van de Vijver,et al.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer , 2009, Oncogene.

[76]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[77]  Qiang Yu,et al.  BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A , 2009, Breast Cancer Research.

[78]  Kristina M. Cook,et al.  Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1α (HIF-1α) and p300 by a Zinc Ejection Mechanism* , 2009, The Journal of Biological Chemistry.

[79]  J. Inazawa,et al.  Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. , 2009, Carcinogenesis.

[80]  Tao Xi,et al.  Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells , 2009, IUBMB life.

[81]  Peter A. Jones,et al.  DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation , 2009, Molecular Cancer Therapeutics.

[82]  Yukihiro Itoh,et al.  Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[83]  R. Versteeg,et al.  Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. , 2009, Cancer research.

[84]  J. Snyder,et al.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 , 2009, Nature Structural &Molecular Biology.

[85]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[86]  G. Crabtree,et al.  An EZ mark to miss. , 2008, Cell stem cell.

[87]  J. Leal,et al.  S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. , 2008, Carcinogenesis.

[88]  U. Oppermann,et al.  Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. , 2008, Journal of medicinal chemistry.

[89]  B. Ren,et al.  Role of the Histone H3 Lysine 4 Methyltransferase, SET7/9, in the Regulation of NF-κB-dependent Inflammatory Genes , 2008, Journal of Biological Chemistry.

[90]  G. Zhu,et al.  SET8 plays a role in controlling G1/S transition by blocking lysine acetylation in histone through binding to H4 N-terminal tail , 2008, Cell cycle.

[91]  David M. Gooden,et al.  Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. , 2008, Bioorganic & medicinal chemistry letters.

[92]  Takehide Asano,et al.  Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed‐lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma , 2008, Human mutation.

[93]  S. Kato,et al.  Transrepressive Function of TLX Requires the Histone Demethylase LSD1 , 2008, Molecular and Cellular Biology.

[94]  P. Thompson,et al.  In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. , 2008, Journal of the American Chemical Society.

[95]  M. Lazar,et al.  DOT1L/KMT4 Recruitment and H3K79 Methylation Are Ubiquitously Coupled with Gene Transcription in Mammalian Cells , 2008, Molecular and Cellular Biology.

[96]  Hong Lei,et al.  Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. , 2008, Molecular cell.

[97]  T. Umehara,et al.  Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. , 2008, Biochemical and biophysical research communications.

[98]  K. Helin,et al.  The histone methyltransferase SET8 is required for S-phase progression , 2007, The Journal of cell biology.

[99]  Joobae Park,et al.  Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer , 2007, International journal of cancer.

[100]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[101]  Hideaki Kato,et al.  Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[102]  Min Gyu Lee,et al.  p53 is regulated by the lysine demethylase LSD1 , 2007, Nature.

[103]  Or Gozani,et al.  Modulation of p53 function by SET8-mediated methylation at lysine 382. , 2007, Molecular cell.

[104]  G. Wang,et al.  NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis , 2007, Nature Cell Biology.

[105]  P. Cole,et al.  Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. , 2007, Biochemistry.

[106]  T. Jenuwein,et al.  Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. , 2007, Cancer cell.

[107]  S. Baylin,et al.  Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes , 2007, Proceedings of the National Academy of Sciences.

[108]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[109]  Sieger Leenstra,et al.  Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. , 2007, Cancer research.

[110]  D. M. Schmidt,et al.  trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. , 2007, Biochemistry.

[111]  K. Bible,et al.  Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. , 2007, Blood.

[112]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[113]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[114]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[115]  A. Knezevich,et al.  Suv39H1 and HP1γ are responsible for chromatin‐mediated HIV‐1 transcriptional silencing and post‐integration latency , 2007, The EMBO journal.

[116]  S. Berger,et al.  Repression of p53 activity by Smyd2-mediated methylation , 2006, Nature.

[117]  Yi Zhang,et al.  JmjC-domain-containing proteins and histone demethylation , 2006, Nature Reviews Genetics.

[118]  G. Peters,et al.  Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all , 2006, Nature Reviews Molecular Cell Biology.

[119]  Juri Rappsilber,et al.  The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3 , 2006, Nature.

[120]  A. Riggs,et al.  The Histone Methyltransferase SETDB1 and the DNA Methyltransferase DNMT3A Interact Directly and Localize to Promoters Silenced in Cancer Cells* , 2006, Journal of Biological Chemistry.

[121]  P. Gottlieb,et al.  Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex , 2006, Molecular Cancer.

[122]  Min Gyu Lee,et al.  Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. , 2006, Chemistry & biology.

[123]  F. Aniello,et al.  Expression of four histone lysine-methyltransferases in parotid gland tumors. , 2006, Anticancer research.

[124]  P. Cole,et al.  A mechanism-based inactivator for histone demethylase LSD1. , 2006, Journal of the American Chemical Society.

[125]  S. Rajski,et al.  Design, Synthesis, and Preliminary Biological Evaluation of a DNA Methyltransferase‐Directed Alkylating Agent , 2006, Chembiochem : a European journal of chemical biology.

[126]  Yusuke Nakamura,et al.  Enhanced SMYD3 expression is essential for the growth of breast cancer cells , 2006, Cancer science.

[127]  Cyrus Martin,et al.  The diverse functions of histone lysine methylation , 2005, Nature Reviews Molecular Cell Biology.

[128]  Scott J. Russo,et al.  Chromatin Remodeling Is a Key Mechanism Underlying Cocaine-Induced Plasticity in Striatum , 2005, Neuron.

[129]  Antoine H. F. M. Peters,et al.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription , 2005, Nature.

[130]  Axel Imhof,et al.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.

[131]  S. Hilton,et al.  Observations on the reactivity of thiyl radicals derived from 3,6-epidithiodiketopiperazine-2,5-diones and related congeners. , 2005, Bioorganic & medicinal chemistry letters.

[132]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[133]  J. Hess.  MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.

[134]  Yusuke Nakamura,et al.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells , 2004, Nature Cell Biology.

[135]  H. Osswald,et al.  S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. , 2004, Trends in pharmacological sciences.

[136]  Hong Lei,et al.  Histone H3-K9 Methyltransferase ESET Is Essential for Early Development , 2004, Molecular and Cellular Biology.

[137]  S. Prigge,et al.  Structure, evolution, and inhibitor interaction of S‐adenosyl‐L‐homocysteine hydrolase from Plasmodium falciparum , 2003, Proteins.

[138]  E. Heard,et al.  Role of Histone Methyltransferase G9a in CpG Methylation of the Prader-Willi Syndrome Imprinting Center* , 2003, The Journal of Biological Chemistry.

[139]  Yi Zhang,et al.  Structure of the Catalytic Domain of Human DOT1L, a Non-SET Domain Nucleosomal Histone Methyltransferase , 2003, Cell.

[140]  Geoff Kelly,et al.  Structure and catalytic mechanism of the human histone methyltransferase SET7/9 , 2003, Nature.

[141]  Ioannis Panagopoulos,et al.  Fusion of the NUP98 gene and the homeobox gene HOXC13 in acute myeloid leukemia with t(11;12)(p15;q13) , 2003, Genes, chromosomes & cancer.

[142]  A. Razin,et al.  The imprinting mechanism of the Prader–Willi/Angelman regional control center , 2002, The EMBO journal.

[143]  Kevin Struhl,et al.  Methylation of H3-Lysine 79 Is Mediated by a New Family of HMTases without a SET Domain , 2002, Current Biology.

[144]  I. Pogribny,et al.  Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice. , 2001, The Journal of nutrition.

[145]  P. Chambon,et al.  NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. , 2001, Genomics.

[146]  A. Rust,et al.  Inaugural article: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma , 2012 .

[147]  S. Kako,et al.  EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization , 2010, Leukemia.

[148]  Pierre-Olivier Angrand,et al.  The control of histone lysine methylation in epigenetic regulation. , 2007, Biochimie.

[149]  J. Hess.  Mechanisms of transformation by MLL. , 2004, Critical reviews in eukaryotic gene expression.

[150]  T. Jenuwein,et al.  Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases , 2004, Nature Genetics.

[151]  J. Aarbakke,et al.  Differential cell cycle perturbation by transmethylation inhibitors. , 1990, Biochemical pharmacology.

[152]  G. Sherbet.  Epigenetic processes and their relevance to the study of neoplasia. , 1970 .